The potential of menin inhibitors in specific molecular subsets of AML & ALL

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares her perspectives on the potential of menin inhibitors in the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). These drugs have shown promising results in early-phase studies in heavily pre-treated patients carrying NPM1 mutations and KMT2A gene rearrangements and are currently being evaluated in multiple studies in combination with other agents. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.